Start Submission Become a Reviewer

Reading: Evidence based management of acute COVID-19


A- A+
Alt. Display

Review Articles

Evidence based management of acute COVID-19


H. Sathischandra

National Hospital Sri Lanka, LK
About H.
Consultant Physician
X close


SARS-CoV-2, the causative agent of COVID-19, was sequenced in early January 2020 and the WHO declared a pandemic in early March 2020.The original virus which caused the first outbreak in Wuhan has mutated significantly, with the delta variant giving rise to a major wave globally with much morbidity and mortality. By the last week of December 2021, nearly 280 million cases were reported with well over 5 million deaths. With the emergence of the new omicron variant which is said to be more transmissible, there is a risk of another major wave with the potential for health facilities around the world being overwhelmed.

In such a background, health systems must be better prepared to face the challenge, and that should include refining treatment protocols. Preventing hospitalizations with early use of oral antiviral drugs and optimising treatment of severe COVID-19 are equally important. This review aims to outline a management plan based on the stage and severity of the disease by examining the current clinical evidence that has emerged through a multitude of trials. There is general consensus regarding the use of steroids, immunosuppressive therapy and anticoagulation in COVID-19 although there are slight differences in the respective national guidelines.

New research is being carried out with oral antiviral drugs for use in early disease and some of the early results are promising. They could play a decisive role in mitigating the effects of the pandemic in addition to vaccination. As many clinical trials are ongoing it is likely that guidelines will need periodic revision.

How to Cite: Sathischandra H. Evidence based management of acute COVID-19. Asian Journal of Internal Medicine. 2022;1(1):60–5. DOI:
Published on 01 Jan 2022.
Peer Reviewed


  • PDF (EN)

    comments powered by Disqus